Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.

BACKGROUND Noninvasive, focused hyperthermia can be achieved by using an externally applied alternating magnetic field (AMF) if effective concentrations of nanoparticles can be delivered to the target cancer cells. Targeting agents, for example, monoclonal antibodies or peptides, linked to magnetic iron oxide nanoparticles (NP), represent a promising strategy to target cancer cells and hyperthermia. METHODS We have developed a new radioconjugate NP ((111)In-DOTA-di-scFv-NP), using recombinantly generated antibody fragments, di-scFv-c, for the imaging and therapy of anti-MUC-1-expressing cancers, because aberrant MUC-1 is abundantly expressed on the majority of human epithelial cancers. Anti-MUC-1 di-scFv-c (50 kDa) were engineered, generated, and selected to link maleimide functionalized nanoparticles (NP-M). DOTA chelate was conjugated with di-scFv-c for radionuclide chelation to trace the radioimmunonanoparticles (RINPs) in vivo. RESULTS Heat-inducing NP-M were prepared with maleimide density >15 per particle for site-specific thiolation. The specific activity of the RINP was 4-5 microCi (111)In/mg with >10 molecules of di-scFv per NP. We characterized the RINP by polyacrylamide gel electrophoresis, cellulose acetate electrophoresis, size-exclusion chromatography, and tumor-cell binding. RINP had a >90% di-scFv conjugated to NP and an immunoreactivity >80% relative to unmodified di-scFv-c on HBT 3477 and DU145 tumor cells. Pharmacokinetics and whole-body autoradiography studies demonstrated that a 5% injected dose was targeted in tumor after 24 hours. CONCLUSIONS Further development of this new preparation of RINP may provide uniquely high tumor-targeting NP for AMF-driven tumor hyperthermia with less spleen and kidney accumulation.

[1]  G. Denardo,et al.  Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma , 2007, Journal of Nuclear Medicine.

[2]  Arutselvan Natarajan,et al.  Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  S. Denardo,et al.  Recombinant antibodies: from the laboratory to the clinic. , 2006, Cancer biotherapy & radiopharmaceuticals.

[4]  Arutselvan Natarajan,et al.  Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding. , 2006, Protein engineering, design & selection : PEDS.

[5]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[6]  R. Ivkov,et al.  Development of Tumor Targeting Bioprobes (111In-Chimeric L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy , 2005, Clinical Cancer Research.

[7]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[8]  H. Honda,et al.  Heat immunotherapy using magnetic nanoparticles and dendritic cells for T-lymphoma. , 2005, Journal of bioscience and bioengineering.

[9]  Anna Moore,et al.  In Vivo Targeting of Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe , 2004, Cancer Research.

[10]  Č. Venclovas,et al.  Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Peter Bohlen,et al.  Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. , 2001, Cancer research.

[12]  J. Wong,et al.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. , 2001, Bioconjugate chemistry.

[13]  K. Tsumoto,et al.  Construction of a diabody (small recombinant bispecific antibody) using a refolding system. , 2000, Protein engineering.

[14]  G W Beresford,et al.  Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization. , 2000, Journal of biochemistry.

[15]  K. Lamborn,et al.  Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. , 2000, Cancer biotherapy & radiopharmaceuticals.

[16]  G. Landes,et al.  Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. , 1999, Cancer research.

[17]  R Weissleder,et al.  High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. , 1999, Bioconjugate chemistry.

[18]  J. Taylor‐Papadimitriou,et al.  A short synthetic peptide (DTRPAP) induces anti-mucin (MUC-1) antibody, which is reactive with human ovarian and breast cancer cells. , 1998, Cancer biochemistry biophysics.

[19]  S. Barratt-Boyes.  Making the most of mucin: a novel target for tumor immunotherapy , 1996, Cancer Immunology, Immunotherapy.

[20]  L E Williams,et al.  Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.

[21]  G. Denardo,et al.  Comparative toxicity studies of yttrium‐90 mx‐dtpa and 2‐it‐bad conjugated monoclonal antibody (bre‐3) , 1994, Cancer.

[22]  W Wood,et al.  Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. A. Edwards.  The Technique of Whole-Body Autoradiography , 1988 .

[24]  J. Overgaard,et al.  Effect of hyperthermia on malignant cells in vivo: A review and a hypothesis , 1977, Cancer.

[25]  G. Denardo,et al.  Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. , 2005, Bioconjugate chemistry.

[26]  Hiroyuki Honda,et al.  Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. , 2003, Journal of bioscience and bioengineering.

[27]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[28]  Thomas E. Creighton,et al.  Protein structure : a practical approach , 1997 .

[29]  C. Streffer,et al.  The biological basis for tumour therapy by hyperthermia and radiation. , 1987, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.